Xenon Pharmaceuticals Inc. (XENE) NASDAQ
$41.63 0.14 (0.34%)
Market Cap: $3.14B
As of 04/17/24 04:00 PM EDT. Market closed.
Xenon Pharmaceuticals Inc. (XENE)
NASDAQ
$41.63
0.14 (0.34%)
Market Cap: $3.14B
As of 04/17/24 04:00 PM EDT. Market closed.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes ... read more
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
GAROFALO ELIZABETH A. | Director | Mar 08, 2024 | Option Exercise | $46.16 | 1,408 | 64,993 | 2,092 | Mar 11, 2024, 08:09 PM |
GAROFALO ELIZABETH A. | Director | Mar 08, 2024 | Option Exercise | $18.56 | 3,500 | 64,960 | 3,500 | Mar 11, 2024, 08:09 PM |
GAROFALO ELIZABETH A. | Director | Mar 08, 2024 | Sale | $45.69 | 2,092 | 95,583 | 0 | Mar 11, 2024, 08:09 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 07, 2024 | Option Exercise | $45.96 | 1,504 | 69,124 | 15,535 | Mar 08, 2024, 05:31 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 07, 2024 | Option Exercise | $9.85 | 8,641 | 85,114 | 16,824 | Mar 08, 2024, 05:31 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 07, 2024 | Sale | $46.28 | 7,137 | 330,290 | 14,516 | Mar 08, 2024, 05:31 PM |
GANNON STEVEN | Director | Mar 07, 2024 | Sale | $46.28 | 13,000 | 601,615 | 14,000 | Mar 08, 2024, 05:28 PM |
AZAB MOHAMMAD | Director | Dec 19, 2023 | Option Exercise | $9.85 | 4,320 | 42,552 | 74,225 | Dec 20, 2023, 05:04 PM |
PATOU GARY | Director | Dec 14, 2023 | Sale | $41.05 | 7,598 | 311,898 | 4,902 | Dec 15, 2023, 09:50 PM |
PATOU GARY | Director | Dec 13, 2023 | Option Exercise | $39.68 | 3,022 | 119,913 | 28,673 | Dec 15, 2023, 05:38 PM |
PATOU GARY | Director | Dec 13, 2023 | Option Exercise | $9.55 | 14,402 | 137,487 | 29,951 | Dec 15, 2023, 05:38 PM |
PATOU GARY | Director | Dec 13, 2023 | Sale | $41.05 | 7,598 | 311,898 | 4,902 | Dec 15, 2023, 05:38 PM |
PATOU GARY | Director | Dec 13, 2023 | Sale | $39.29 | 11,380 | 447,085 | 23,573 | Dec 15, 2023, 05:38 PM |
Svoronos Dawn | Director | Aug 24, 2023 | Sale | $38.70 | 25,000 | 967,500 | 25,000 | Aug 24, 2023, 04:33 PM |
PIMSTONE SIMON N. | Director | May 31, 2023 | Option Exercise | $38.37 | 29,309 | 1,124,586 | 32,856 | Jun 01, 2023, 07:25 PM |
PIMSTONE SIMON N. | Director | Jun 01, 2023 | Option Exercise | $38.53 | 22,605 | 870,971 | 30,255 | Jun 01, 2023, 07:25 PM |
PIMSTONE SIMON N. | Director | Jun 01, 2023 | Option Exercise | $16.03 | 54,318 | 870,855 | 51,000 | Jun 01, 2023, 07:25 PM |
PIMSTONE SIMON N. | Director | May 31, 2023 | Option Exercise | $14.80 | 79,835 | 1,181,875 | 56,000 | Jun 01, 2023, 07:25 PM |
PIMSTONE SIMON N. | Director | May 31, 2023 | Sale | $38.70 | 62,526 | 2,420,051 | 6,000 | Jun 01, 2023, 07:25 PM |
PIMSTONE SIMON N. | Director | May 30, 2023 | Sale | $39.28 | 37,006 | 1,453,672 | 37,000 | Jun 01, 2023, 07:25 PM |
PIMSTONE SIMON N. | Director | Jun 01, 2023 | Sale | $38.82 | 31,713 | 1,231,247 | 6,000 | Jun 01, 2023, 07:25 PM |
MORTIMER IAN | PRESIDENT & CEO | May 24, 2023 | Option Exercise | $41.84 | 12,383 | 518,105 | 41,282 | May 26, 2023, 07:10 PM |
MORTIMER IAN | PRESIDENT & CEO | May 24, 2023 | Option Exercise | $9.60 | 69,340 | 665,536 | 48,592 | May 26, 2023, 07:10 PM |
MORTIMER IAN | PRESIDENT & CEO | May 24, 2023 | Sale | $41.41 | 31,655 | 1,310,931 | 31,302 | May 26, 2023, 07:10 PM |
KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Mar 24, 2023 | Sale | $35.01 | 700 | 24,507 | 0 | Mar 24, 2023, 07:18 PM |
PIMSTONE SIMON N. | Director | Mar 07, 2023 | Option Exercise | $37.13 | 3,778 | 140,277 | 63,248 | Mar 09, 2023, 06:21 PM |
PIMSTONE SIMON N. | Director | Mar 07, 2023 | Option Exercise | $2.64 | 72,016 | 190,225 | 64,866 | Mar 09, 2023, 06:21 PM |
PIMSTONE SIMON N. | Director | Mar 07, 2023 | Sale | $36.98 | 19,232 | 711,199 | 55,006 | Mar 09, 2023, 06:21 PM |
AZAB MOHAMMAD | Director | Dec 12, 2022 | Option Exercise | $2.68 | 3,086 | 8,270 | 69,905 | Dec 13, 2022, 04:29 PM |
PATOU GARY | Director | Nov 25, 2022 | Option Exercise | $34.37 | 120 | 4,124 | 25,510 | Nov 28, 2022, 08:41 PM |
PATOU GARY | Director | Nov 25, 2022 | Option Exercise | $2.68 | 2,057 | 5,513 | 25,630 | Nov 28, 2022, 08:41 PM |
PATOU GARY | Director | Nov 25, 2022 | Sale | $34.79 | 1,937 | 67,390 | 23,573 | Nov 28, 2022, 08:41 PM |
PATOU GARY | Director | Nov 23, 2022 | Sale | $34.33 | 2,057 | 70,610 | 23,573 | Nov 28, 2022, 08:41 PM |
AULIN SHERRY | Chief Financial Officer | Sep 02, 2022 | Option Exercise | $39.53 | 3,293 | 130,172 | 15,355 | Sep 07, 2022, 04:26 PM |
AULIN SHERRY | Chief Financial Officer | Sep 02, 2022 | Option Exercise | $6.97 | 18,648 | 130,061 | 18,648 | Sep 07, 2022, 04:26 PM |
AULIN SHERRY | Chief Financial Officer | Sep 02, 2022 | Sale | $39.57 | 15,355 | 607,597 | 0 | Sep 07, 2022, 04:26 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 01, 2022 | Option Exercise | $38.81 | 6,121 | 237,556 | 60,675 | Sep 02, 2022, 04:27 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Aug 31, 2022 | Option Exercise | $37.86 | 1,572 | 59,516 | 38,148 | Sep 02, 2022, 04:27 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Aug 31, 2022 | Option Exercise | $3.13 | 22,488 | 70,443 | 39,720 | Sep 02, 2022, 04:27 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 01, 2022 | Option Exercise | $4.75 | 50,000 | 237,500 | 66,796 | Sep 02, 2022, 04:27 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 01, 2022 | Sale | $38.18 | 43,879 | 1,675,476 | 25,572 | Sep 02, 2022, 04:27 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Aug 31, 2022 | Sale | $38.57 | 21,352 | 823,547 | 16,796 | Sep 02, 2022, 04:27 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Aug 12, 2022 | Option Exercise | $38.02 | 7,257 | 275,911 | 67,743 | Aug 16, 2022, 05:36 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Aug 12, 2022 | Option Exercise | $4.24 | 65,000 | 275,750 | 75,000 | Aug 16, 2022, 05:36 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Aug 12, 2022 | Sale | $38.31 | 57,743 | 2,211,979 | 31,875 | Aug 16, 2022, 05:36 PM |
PIMSTONE SIMON N. | Director | Aug 16, 2022 | Sale | $38.51 | 52,058 | 2,004,901 | 26,000 | Aug 16, 2022, 05:31 PM |
PIMSTONE SIMON N. | Director | Aug 15, 2022 | Sale | $37.76 | 33,942 | 1,281,650 | 58,058 | Aug 16, 2022, 05:31 PM |
PIMSTONE SIMON N. | Director | Aug 12, 2022 | Sale | $38.28 | 91,135 | 3,488,598 | 140,000 | Aug 16, 2022, 05:31 PM |
PIMSTONE SIMON N. | Director | Mar 08, 2022 | Sale | $30.80 | 2,500 | 77,000 | 193,135 | Mar 08, 2022, 09:41 PM |
PIMSTONE SIMON N. | Director | Mar 04, 2022 | Option Exercise | $31.42 | 963 | 30,257 | 219,511 | Mar 08, 2022, 07:58 PM |
PIMSTONE SIMON N. | Director | Mar 07, 2022 | Option Exercise | $30.23 | 1,990 | 60,158 | 228,772 | Mar 08, 2022, 07:58 PM |
PIMSTONE SIMON N. | Director | Mar 04, 2022 | Option Exercise | $3.67 | 10,288 | 37,757 | 220,474 | Mar 08, 2022, 07:58 PM |
PIMSTONE SIMON N. | Director | Mar 07, 2022 | Option Exercise | $3.67 | 20,576 | 75,514 | 230,762 | Mar 08, 2022, 07:58 PM |
PIMSTONE SIMON N. | Director | Mar 08, 2022 | Sale | $25.82 | 14,551 | 375,636 | 195,635 | Mar 08, 2022, 07:58 PM |
PIMSTONE SIMON N. | Director | Mar 07, 2022 | Sale | $30.50 | 31,086 | 948,260 | 223,735 | Mar 08, 2022, 07:58 PM |
PIMSTONE SIMON N. | Director | Mar 04, 2022 | Sale | $30.61 | 9,325 | 285,425 | 214,979 | Mar 08, 2022, 07:58 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 04, 2022 | Option Exercise | $31.42 | 696 | 21,868 | 32,770 | Mar 08, 2022, 07:35 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 04, 2022 | Option Exercise | $3.67 | 7,406 | 27,180 | 38,942 | Mar 08, 2022, 07:35 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 04, 2022 | Sale | $30.50 | 21,710 | 662,208 | 32,232 | Mar 08, 2022, 07:35 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 04, 2022 | Option Exercise | $31.42 | 6,685 | 210,043 | 28,315 | Mar 08, 2022, 07:32 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 07, 2022 | Option Exercise | $30.23 | 9,647 | 291,629 | 42,853 | Mar 08, 2022, 07:32 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 07, 2022 | Option Exercise | $6.86 | 42,500 | 291,400 | 51,805 | Mar 08, 2022, 07:32 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 04, 2022 | Option Exercise | $8.40 | 25,000 | 210,000 | 35,000 | Mar 08, 2022, 07:32 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 04, 2022 | Sale | $30.79 | 18,315 | 563,919 | 10,000 | Mar 08, 2022, 07:32 PM |
EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 07, 2022 | Sale | $30.54 | 32,853 | 1,003,475 | 41,048 | Mar 08, 2022, 07:32 PM |
KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Jan 21, 2022 | Buy | $28.81 | 700 | 20,167 | 700 | Jan 21, 2022, 05:04 PM |
AZAB MOHAMMAD | Director | Dec 15, 2021 | Option Exercise | $3.67 | 3,086 | 11,326 | 66,819 | Dec 17, 2021, 04:04 PM |
PATOU GARY | Director | Dec 08, 2021 | Option Exercise | $3.67 | 2,057 | 7,549 | 25,630 | Dec 10, 2021, 04:20 PM |
Von Seggern Christopher | Chief Commercial Officer | Dec 06, 2021 | Buy | $24.40 | 4,000 | 97,600 | 4,000 | Dec 07, 2021, 04:13 PM |
PIMSTONE SIMON N. | Director | Nov 15, 2021 | Sale | $31.33 | 17,557 | 550,061 | 210,186 | Nov 16, 2021, 08:40 PM |
PATOU GARY | Director | Mar 17, 2021 | Option Exercise | $19.49 | 100 | 1,949 | 100 | Jun 04, 2021, 07:20 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | May 28, 2021 | Option Exercise | $18.91 | 4,216 | 79,725 | 38,299 | Jun 01, 2021, 04:11 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | May 28, 2021 | Option Exercise | $3.81 | 25,719 | 97,907 | 40,491 | Jun 01, 2021, 04:11 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | May 28, 2021 | Sale | $18.81 | 6,067 | 114,120 | 35,144 | Jun 01, 2021, 04:11 PM |
PIMSTONE SIMON N. | CEO | May 24, 2021 | Option Exercise | $19.17 | 5,076 | 97,307 | 227,743 | May 26, 2021, 04:11 PM |
PIMSTONE SIMON N. | CEO | May 24, 2021 | Option Exercise | $3.76 | 22,633 | 85,100 | 232,819 | May 26, 2021, 04:11 PM |
Hayden Michael R | Director | Feb 18, 2021 | Option Exercise | $2.93 | 41,152 | 120,472 | 92,076 | Feb 18, 2021, 05:59 PM |
Hayden Michael R | Director | Feb 16, 2021 | Option Exercise | $2.68 | 5,144 | 13,786 | 112,706 | Feb 18, 2021, 05:59 PM |
AZAB MOHAMMAD | Director | Dec 15, 2020 | Option Exercise | $3.76 | 3,086 | 11,603 | 63,733 | Dec 15, 2020, 04:39 PM |
TARNOW MICHAEL M | Director | Oct 28, 2020 | Option Exercise | $3.76 | 10,288 | 38,683 | 80,001 | Oct 29, 2020, 04:27 PM |
PATOU GARY | Director | Oct 28, 2020 | Option Exercise | $3.76 | 2,057 | 7,734 | 23,573 | Oct 29, 2020, 04:20 PM |
TARNOW MICHAEL M | Director | Jun 09, 2020 | Option Exercise | $3.52 | 5,144 | 18,107 | 69,713 | Jun 10, 2020, 05:17 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Jun 01, 2020 | Option Exercise | $13.70 | 1,630 | 22,331 | 16,796 | Jun 02, 2020, 05:40 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Jun 01, 2020 | Option Exercise | $3.56 | 8,230 | 29,299 | 18,426 | Jun 02, 2020, 05:40 PM |
HOLLER FRANK A | Director | May 29, 2020 | Option Exercise | $3.56 | 3,086 | 10,986 | 122,041 | Jun 02, 2020, 04:54 PM |
PIMSTONE SIMON N. | CEO | Jun 01, 2020 | Sale | $14.43 | 3,000 | 43,290 | 255,186 | Jun 02, 2020, 04:50 PM |
PIMSTONE SIMON N. | CEO | May 29, 2020 | Sale | $13.99 | 5,000 | 69,950 | 258,186 | Jun 02, 2020, 04:50 PM |
PIMSTONE SIMON N. | CEO | May 26, 2020 | Option Exercise | $14.90 | 1,108 | 16,509 | 263,186 | May 28, 2020, 05:02 PM |
PIMSTONE SIMON N. | CEO | May 26, 2020 | Option Exercise | $3.56 | 6,172 | 21,972 | 264,294 | May 28, 2020, 05:02 PM |
AZAB MOHAMMAD | Director | Dec 16, 2019 | Option Exercise | $3.56 | 3,086 | 10,986 | 60,647 | Dec 17, 2019, 05:04 PM |
PATOU GARY | Director | Dec 04, 2019 | Option Exercise | $3.56 | 2,057 | 7,323 | 21,516 | Dec 06, 2019, 05:12 PM |
TARNOW MICHAEL M | Director | Nov 21, 2019 | Option Exercise | $3.55 | 7,201 | 25,533 | 69,713 | Nov 22, 2019, 01:30 PM |
PIMSTONE SIMON N. | CEO | Sep 20, 2019 | Sale | $9.51 | 10,395 | 98,856 | 258,122 | Sep 24, 2019, 06:14 PM |
HOLLER FRANK A | Director | Sep 20, 2019 | Sale | $9.39 | 5,206 | 48,884 | 118,955 | Sep 20, 2019, 04:15 PM |
HOLLER FRANK A | Director | Sep 19, 2019 | Sale | $9.27 | 7,600 | 70,452 | 124,161 | Sep 20, 2019, 04:15 PM |
PIMSTONE SIMON N. | CEO | Sep 17, 2019 | Option Exercise | $9.44 | 17,230 | 162,651 | 268,517 | Sep 18, 2019, 07:06 PM |
PIMSTONE SIMON N. | CEO | Sep 17, 2019 | Option Exercise | $3.53 | 57,612 | 203,381 | 272,209 | Sep 18, 2019, 07:06 PM |
HOLLER FRANK A | Director | Sep 18, 2019 | Sale | $9.28 | 4,368 | 40,535 | 131,761 | Sep 18, 2019, 06:43 PM |
HOLLER FRANK A | Director | Sep 17, 2019 | Sale | $9.32 | 5,069 | 47,243 | 136,129 | Sep 18, 2019, 06:43 PM |
AZAB MOHAMMAD | Director | Sep 13, 2019 | Sale | $9.31 | 23 | 214 | 57,561 | Sep 17, 2019, 04:46 PM |
HOLLER FRANK A | Director | Sep 12, 2019 | Option Exercise | $9.38 | 9,649 | 90,508 | 141,198 | Sep 13, 2019, 08:13 PM |
HOLLER FRANK A | Director | Sep 12, 2019 | Option Exercise | $3.07 | 31,892 | 98,052 | 148,979 | Sep 13, 2019, 08:13 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 12, 2019 | Option Exercise | $9.38 | 1,868 | 17,522 | 10,196 | Sep 13, 2019, 06:58 PM |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 12, 2019 | Option Exercise | $3.07 | 6,172 | 18,948 | 12,064 | Sep 13, 2019, 06:58 PM |
TARNOW MICHAEL M | Director | May 21, 2019 | Option Exercise | $3.21 | 2,057 | 6,603 | 64,569 | May 23, 2019, 11:56 AM |
Hayden Michael R | Director | Mar 19, 2019 | Option Exercise | $3.38 | 20,576 | 69,547 | 50,924 | Mar 20, 2019, 05:13 PM |
PATOU GARY | Director | Dec 14, 2018 | Option Exercise | $3.07 | 2,057 | 6,315 | 19,459 | Dec 18, 2018, 04:06 PM |
COHEN CHARLES J. | VP, Biology | Dec 11, 2018 | Option Exercise | $7.00 | 1,644 | 11,508 | 6,550 | Dec 13, 2018, 01:56 PM |
COHEN CHARLES J. | VP, Biology | Dec 11, 2018 | Option Exercise | $3.07 | 4,115 | 12,633 | 8,194 | Dec 13, 2018, 01:56 PM |
AZAB MOHAMMAD | Director | Dec 06, 2018 | Option Exercise | $3.07 | 3,086 | 9,474 | 57,584 | Dec 10, 2018, 09:10 PM |
TARNOW MICHAEL M | Director | Jun 21, 2018 | Option Exercise | $3.43 | 12,345 | 42,354 | 67,512 | Jun 22, 2018, 04:40 PM |
AZAB MOHAMMAD | Director | Jun 21, 2018 | Option Exercise | $3.70 | 10,288 | 38,066 | 54,498 | Jun 22, 2018, 04:39 PM |
PATOU GARY | Director | Jun 14, 2018 | Option Exercise | $8.30 | 2,856 | 23,705 | 17,402 | Jun 15, 2018, 07:32 PM |
PATOU GARY | Director | Jun 14, 2018 | Option Exercise | $3.70 | 8,230 | 30,451 | 20,258 | Jun 15, 2018, 07:32 PM |
ROBIN SHERRINGTON | EVP Bus. & Corp. Development | Mar 15, 2018 | Option Exercise | $4.63 | 1,928 | 8,917 | 5,892 | Mar 16, 2018, 04:33 PM |
ROBIN SHERRINGTON | EVP Bus. & Corp. Development | Mar 15, 2018 | Option Exercise | $3.77 | 3,086 | 11,634 | 7,820 | Mar 16, 2018, 04:33 PM |
HOLLER FRANK A | Director | Mar 14, 2018 | Option Exercise | $3.77 | 3,086 | 11,634 | 118,955 | Mar 16, 2018, 04:23 PM |
PIMSTONE SIMON N. | CEO | Mar 12, 2018 | Option Exercise | $3.77 | 10,288 | 38,786 | 228,135 | Mar 14, 2018, 04:52 PM |
COHEN CHARLES J. | VP, Biology | Feb 12, 2018 | Option Exercise | $3.50 | 22,669 | 79,342 | 4,079 | Feb 14, 2018, 05:55 PM |
COHEN CHARLES J. | VP, Biology | Feb 12, 2018 | Option Exercise | $3.71 | 26,748 | 99,235 | 26,748 | Feb 14, 2018, 05:55 PM |
AZAB MOHAMMAD | Director | Nov 15, 2017 | Buy | $2.22 | 15,000 | 33,280 | 44,210 | Nov 16, 2017, 04:56 PM |
AZAB MOHAMMAD | Director | Sep 22, 2017 | Buy | $2.95 | 8,000 | 23,600 | 29,210 | Sep 25, 2017, 05:00 PM |
AZAB MOHAMMAD | Director | Sep 21, 2017 | Buy | $2.95 | 2,000 | 5,900 | 21,210 | Sep 25, 2017, 05:00 PM |
AZAB MOHAMMAD | Director | Aug 18, 2017 | Buy | $2.90 | 6,312 | 18,302 | 19,210 | Aug 21, 2017, 04:49 PM |
AZAB MOHAMMAD | Director | Aug 17, 2017 | Buy | $2.65 | 23 | 61 | 12,898 | Aug 21, 2017, 04:49 PM |
WINQUIST RAYMOND | Head, Translational Research | Aug 18, 2017 | Buy | $2.99 | 1,000 | 2,995 | 1,000 | Aug 21, 2017, 04:48 PM |
EMPFIELD JAMES R. | SVP, Drug Discovery | Aug 15, 2017 | Buy | $2.48 | 10,000 | 24,824 | 10,000 | Aug 17, 2017, 05:33 PM |
BVF PARTNERS L P/IL | 10% Owner | Aug 15, 2017 | Buy | $2.41 | 18,858 | 45,489 | 1,674,468 | Aug 16, 2017, 06:55 PM |
BVF PARTNERS L P/IL | 10% Owner | Aug 14, 2017 | Buy | $2.70 | 41,344 | 111,778 | 1,663,039 | Aug 16, 2017, 06:55 PM |
Svoronos Dawn | Director | Aug 14, 2017 | Buy | $2.82 | 50,000 | 140,770 | 50,000 | Aug 15, 2017, 04:54 PM |
PATOU GARY | Director | Aug 10, 2017 | Buy | $2.78 | 7,500 | 20,836 | 12,500 | Aug 14, 2017, 06:07 PM |
MORTIMER IAN | CFO & COO | Aug 10, 2017 | Buy | $2.90 | 10,000 | 29,000 | 14,300 | Aug 14, 2017, 06:07 PM |
MORTIMER IAN | CFO & COO | Aug 10, 2017 | Buy | $2.85 | 5,000 | 14,225 | 6,000 | Aug 14, 2017, 06:07 PM |
SCHELLER RICHARD H | Director | Aug 10, 2017 | Buy | $2.85 | 7,000 | 19,950 | 7,000 | Aug 14, 2017, 06:07 PM |
PIMSTONE SIMON N. | President & CEO | Aug 10, 2017 | Buy | $2.90 | 6,000 | 17,400 | 217,847 | Aug 14, 2017, 06:06 PM |
Hayden Michael R | Director | Aug 14, 2017 | Buy | $2.75 | 15,000 | 41,247 | 161,187 | Aug 14, 2017, 06:06 PM |
GANNON STEVEN | Director | Aug 11, 2017 | Buy | $2.82 | 15,000 | 42,267 | 15,000 | Aug 14, 2017, 06:05 PM |
PATOU GARY | Director | Aug 08, 2017 | Buy | $3.00 | 5,000 | 15,002 | 5,000 | Aug 10, 2017, 07:58 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 27, 2017 | Buy | $3.04 | 85,461 | 259,468 | 1,635,032 | Jun 30, 2017, 12:00 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 27, 2017 | Buy | $4.00 | 85,461 | 341,844 | 1,635,032 | Jun 29, 2017, 06:21 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 22, 2017 | Buy | $4.00 | 8,263 | 33,052 | 1,588,237 | Jun 23, 2017, 07:16 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 21, 2017 | Buy | $4.00 | 12,148 | 48,592 | 1,583,712 | Jun 23, 2017, 07:16 PM |
TARNOW MICHAEL M | Director | Jun 19, 2017 | Option Exercise | $3.51 | 1,028 | 3,608 | 56,195 | Jun 20, 2017, 04:37 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 15, 2017 | Buy | $3.84 | 11,779 | 45,196 | 1,569,268 | Jun 19, 2017, 07:33 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 19, 2017 | Buy | $3.85 | 3,595 | 13,841 | 1,577,332 | Jun 19, 2017, 07:33 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 16, 2017 | Buy | $3.85 | 11,034 | 42,481 | 1,575,365 | Jun 19, 2017, 07:33 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 07, 2017 | Buy | $3.85 | 207,789 | 800,237 | 1,562,494 | Jun 08, 2017, 06:58 PM |
BVF PARTNERS L P/IL | 10% Owner | Jun 06, 2017 | Buy | $3.75 | 150,909 | 565,909 | 1,449,048 | Jun 08, 2017, 06:58 PM |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | May 12, 2017 | Option Exercise | $4.18 | 1,345 | 5,622 | 4,734 | May 16, 2017, 04:32 PM |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | May 12, 2017 | Option Exercise | $3.21 | 2,057 | 6,603 | 6,079 | May 16, 2017, 04:32 PM |
Hayden Michael R | Director | Mar 14, 2017 | Option Exercise | $3.44 | 11,830 | 40,711 | 30,348 | Mar 15, 2017, 07:53 PM |
Hayden Michael R | Director | Mar 14, 2017 | Option Exercise | $3.73 | 48,868 | 182,200 | 146,187 | Mar 15, 2017, 07:53 PM |
HOLLER FRANK A | Director | Dec 15, 2016 | Sale | $7.85 | 30,000 | 235,500 | 115,869 | Dec 19, 2016, 05:07 PM |
TARNOW MICHAEL M | Director | Dec 12, 2016 | Option Exercise | $3.21 | 14,403 | 46,234 | 69,570 | Dec 13, 2016, 04:57 PM |
PATOU GARY | Director | Dec 06, 2016 | Option Exercise | $7.90 | 4,403 | 34,784 | 12,028 | Dec 08, 2016, 04:52 PM |
PATOU GARY | Director | Dec 06, 2016 | Option Exercise | $3.21 | 12,345 | 39,627 | 16,431 | Dec 08, 2016, 04:52 PM |
AZAB MOHAMMAD | Director | Dec 01, 2016 | Option Exercise | $7.80 | 4,408 | 34,382 | 12,875 | Dec 02, 2016, 06:05 PM |
AZAB MOHAMMAD | Director | Dec 01, 2016 | Option Exercise | $3.21 | 12,345 | 39,627 | 17,283 | Dec 02, 2016, 06:05 PM |
HOLLER FRANK A | Director | Aug 19, 2016 | Sale | $7.65 | 11,938 | 91,338 | 145,869 | Aug 23, 2016, 04:51 PM |
HOLLER FRANK A | Director | Aug 18, 2016 | Sale | $7.70 | 9,599 | 73,912 | 157,807 | Aug 18, 2016, 08:24 PM |
HOLLER FRANK A | Director | Aug 17, 2016 | Sale | $7.89 | 1,600 | 12,624 | 167,406 | Aug 18, 2016, 08:24 PM |
HOLLER FRANK A | Director | Aug 16, 2016 | Sale | $8.25 | 6,863 | 56,620 | 169,006 | Aug 18, 2016, 08:24 PM |
PIMSTONE SIMON N. | President & CEO | Jul 29, 2016 | Option Exercise | $7.46 | 4,703 | 35,084 | 211,847 | Aug 02, 2016, 05:10 PM |
PIMSTONE SIMON N. | President & CEO | Jul 29, 2016 | Option Exercise | $3.30 | 12,345 | 40,738 | 216,550 | Aug 02, 2016, 05:10 PM |
MORTIMER IAN | CFO & COO | Jun 24, 2016 | Buy | $6.15 | 1,000 | 6,150 | 1,000 | Jun 28, 2016, 04:41 PM |
MORTIMER IAN | CFO & COO | Jun 24, 2016 | Buy | $6.23 | 4,300 | 26,790 | 4,300 | Jun 28, 2016, 04:41 PM |
Hayden Michael R | Director | May 25, 2016 | Option Exercise | $3.30 | 8,230 | 27,159 | 18,518 | May 27, 2016, 05:07 PM |
TARNOW MICHAEL M | Director | Apr 28, 2016 | Option Exercise | $3.35 | 1,543 | 5,169 | 56,710 | Apr 29, 2016, 06:12 PM |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Dec 16, 2015 | Option Exercise | $7.94 | 229 | 1,818 | 4,022 | Dec 21, 2015, 06:06 AM |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Dec 16, 2015 | Option Exercise | $5.22 | 411 | 2,145 | 4,251 | Dec 21, 2015, 06:06 AM |
AZAB MOHAMMAD | Director | Dec 11, 2015 | Option Exercise | $5.22 | 2,469 | 12,888 | 4,938 | Dec 14, 2015, 05:37 PM |
HOLLER FRANK A | Director | Nov 24, 2015 | Option Exercise | $9.39 | 995 | 9,343 | 175,869 | Nov 25, 2015, 03:50 PM |
HOLLER FRANK A | Director | Nov 24, 2015 | Option Exercise | $5.22 | 2,057 | 10,738 | 176,864 | Nov 25, 2015, 03:50 PM |
PATOU GARY | Director | Nov 04, 2015 | Option Exercise | $8.32 | 1,955 | 16,266 | 4,086 | Nov 06, 2015, 05:20 PM |
PATOU GARY | Director | Nov 04, 2015 | Option Exercise | $5.22 | 3,497 | 18,254 | 6,041 | Nov 06, 2015, 05:20 PM |
TARNOW MICHAEL M | Director | Nov 02, 2015 | Option Exercise | $5.22 | 5,041 | 26,314 | 60,208 | Nov 04, 2015, 06:43 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Sep 22, 2015 | Option Exercise | $9.53 | 8,342 | 79,499 | 28,149 | Sep 24, 2015, 09:56 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Sep 22, 2015 | Option Exercise | $3.24 | 30,388 | 98,513 | 29,218 | Sep 24, 2015, 09:56 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Sep 24, 2015 | Sale | $8.60 | 12,000 | 103,200 | 6,000 | Sep 24, 2015, 09:56 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Sep 23, 2015 | Sale | $9.02 | 4,000 | 36,080 | 18,000 | Sep 24, 2015, 09:56 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Sep 22, 2015 | Sale | $9.33 | 6,149 | 57,384 | 22,000 | Sep 24, 2015, 09:56 PM |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Aug 18, 2015 | Option Exercise | $11.00 | 1,302 | 14,322 | 3,840 | Aug 20, 2015, 01:13 PM |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Aug 18, 2015 | Option Exercise | $4.92 | 3,085 | 15,189 | 4,708 | Aug 20, 2015, 01:13 PM |
PIMSTONE SIMON N. | President & CEO | Aug 18, 2015 | Option Exercise | $11.00 | 8,678 | 95,458 | 204,205 | Aug 20, 2015, 01:11 PM |
PIMSTONE SIMON N. | President & CEO | Aug 18, 2015 | Option Exercise | $4.94 | 20,576 | 101,594 | 210,713 | Aug 20, 2015, 01:11 PM |
HOLLER FRANK A | Director | Aug 18, 2015 | Option Exercise | $11.00 | 868 | 9,548 | 174,807 | Aug 20, 2015, 01:08 PM |
HOLLER FRANK A | Director | Aug 18, 2015 | Option Exercise | $4.98 | 2,057 | 10,244 | 175,675 | Aug 20, 2015, 01:08 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Aug 18, 2015 | Option Exercise | $11.00 | 1,302 | 14,322 | 6,103 | Aug 20, 2015, 01:04 PM |
GOLDBERG Y. PAUL | VP of Clinical Development | Aug 18, 2015 | Option Exercise | $4.92 | 3,085 | 15,189 | 6,971 | Aug 20, 2015, 01:04 PM |
TARNOW MICHAEL M | Director | Jun 17, 2015 | Option Exercise | $4.95 | 1,543 | 7,638 | 55,167 | Jun 19, 2015, 04:31 PM |
Hayden Michael R | Director | Feb 03, 2015 | Option Exercise | $4.81 | 5,144 | 24,743 | 10,288 | Feb 05, 2015, 06:09 PM |
PATOU GARY | Director | Jan 07, 2015 | Option Exercise | $22.28 | 953 | 21,233 | 2,544 | Jan 21, 2015, 08:13 PM |
PATOU GARY | Director | Jan 07, 2015 | Option Exercise | $4.98 | 3,497 | 17,415 | 3,497 | Jan 21, 2015, 08:13 PM |
TARNOW MICHAEL M | Director | Jan 08, 2015 | Option Exercise | $4.98 | 5,041 | 25,104 | 53,624 | Jan 12, 2015, 07:08 PM |
Hayden Michael R | Director | Jan 08, 2015 | Option Exercise | $4.98 | 5,144 | 25,617 | 5,144 | Jan 12, 2015, 07:06 PM |
AZAB MOHAMMAD | Director | Jan 08, 2015 | Option Exercise | $4.98 | 2,469 | 12,296 | 2,469 | Jan 12, 2015, 07:04 PM |
PATOU GARY | Director | Jan 07, 2015 | Option Exercise | $4.98 | 3,497 | 17,415 | 3,497 | Jan 09, 2015, 08:30 PM |
Owner | Relationship | Date | Value($) |
GAROFALO ELIZABETH A. | Director | 03/08/2024 | 64,993 |
GAROFALO ELIZABETH A. | Director | 03/08/2024 | 64,960 |
GAROFALO ELIZABETH A. | Director | 03/08/2024 | 95,583 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/07/2024 | 69,124 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/07/2024 | 85,114 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/07/2024 | 330,290 |
GANNON STEVEN | Director | 03/07/2024 | 601,615 |
AZAB MOHAMMAD | Director | 12/19/2023 | 42,552 |
PATOU GARY | Director | 12/14/2023 | 311,898 |
PATOU GARY | Director | 12/13/2023 | 119,913 |
PATOU GARY | Director | 12/13/2023 | 137,487 |
PATOU GARY | Director | 12/13/2023 | 311,898 |
PATOU GARY | Director | 12/13/2023 | 447,085 |
Svoronos Dawn | Director | 08/24/2023 | 967,500 |
PIMSTONE SIMON N. | Director | 05/31/2023 | 1,124,586 |
PIMSTONE SIMON N. | Director | 06/01/2023 | 870,971 |
PIMSTONE SIMON N. | Director | 06/01/2023 | 870,855 |
PIMSTONE SIMON N. | Director | 05/31/2023 | 1,181,875 |
PIMSTONE SIMON N. | Director | 05/31/2023 | 2,420,051 |
PIMSTONE SIMON N. | Director | 05/30/2023 | 1,453,672 |
PIMSTONE SIMON N. | Director | 06/01/2023 | 1,231,247 |
MORTIMER IAN | PRESIDENT & CEO | 05/24/2023 | 518,105 |
MORTIMER IAN | PRESIDENT & CEO | 05/24/2023 | 665,536 |
MORTIMER IAN | PRESIDENT & CEO | 05/24/2023 | 1,310,931 |
KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 03/24/2023 | 24,507 |
PIMSTONE SIMON N. | Director | 03/07/2023 | 140,277 |
PIMSTONE SIMON N. | Director | 03/07/2023 | 190,225 |
PIMSTONE SIMON N. | Director | 03/07/2023 | 711,199 |
AZAB MOHAMMAD | Director | 12/12/2022 | 8,270 |
PATOU GARY | Director | 11/25/2022 | 4,124 |
PATOU GARY | Director | 11/25/2022 | 5,513 |
PATOU GARY | Director | 11/25/2022 | 67,390 |
PATOU GARY | Director | 11/23/2022 | 70,610 |
AULIN SHERRY | Chief Financial Officer | 09/02/2022 | 130,172 |
AULIN SHERRY | Chief Financial Officer | 09/02/2022 | 130,061 |
AULIN SHERRY | Chief Financial Officer | 09/02/2022 | 607,597 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/01/2022 | 237,556 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 08/31/2022 | 59,516 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 08/31/2022 | 70,443 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/01/2022 | 237,500 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/01/2022 | 1,675,476 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 08/31/2022 | 823,547 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 08/12/2022 | 275,911 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 08/12/2022 | 275,750 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 08/12/2022 | 2,211,979 |
PIMSTONE SIMON N. | Director | 08/16/2022 | 2,004,901 |
PIMSTONE SIMON N. | Director | 08/15/2022 | 1,281,650 |
PIMSTONE SIMON N. | Director | 08/12/2022 | 3,488,598 |
PIMSTONE SIMON N. | Director | 03/08/2022 | 77,000 |
PIMSTONE SIMON N. | Director | 03/04/2022 | 30,257 |
PIMSTONE SIMON N. | Director | 03/07/2022 | 60,158 |
PIMSTONE SIMON N. | Director | 03/04/2022 | 37,757 |
PIMSTONE SIMON N. | Director | 03/07/2022 | 75,514 |
PIMSTONE SIMON N. | Director | 03/08/2022 | 375,636 |
PIMSTONE SIMON N. | Director | 03/07/2022 | 948,260 |
PIMSTONE SIMON N. | Director | 03/04/2022 | 285,425 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/04/2022 | 21,868 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/04/2022 | 27,180 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/04/2022 | 662,208 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 03/04/2022 | 210,043 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 03/07/2022 | 291,629 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 03/07/2022 | 291,400 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 03/04/2022 | 210,000 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 03/04/2022 | 563,919 |
EMPFIELD JAMES R. | EVP, Drug Discovery | 03/07/2022 | 1,003,475 |
KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 01/21/2022 | 20,167 |
AZAB MOHAMMAD | Director | 12/15/2021 | 11,326 |
PATOU GARY | Director | 12/08/2021 | 7,549 |
Von Seggern Christopher | Chief Commercial Officer | 12/06/2021 | 97,600 |
PIMSTONE SIMON N. | Director | 11/15/2021 | 550,061 |
PATOU GARY | Director | 03/17/2021 | 1,949 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 05/28/2021 | 79,725 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 05/28/2021 | 97,907 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 05/28/2021 | 114,120 |
PIMSTONE SIMON N. | CEO | 05/24/2021 | 97,307 |
PIMSTONE SIMON N. | CEO | 05/24/2021 | 85,100 |
Hayden Michael R | Director | 02/18/2021 | 120,472 |
Hayden Michael R | Director | 02/16/2021 | 13,786 |
AZAB MOHAMMAD | Director | 12/15/2020 | 11,603 |
TARNOW MICHAEL M | Director | 10/28/2020 | 38,683 |
PATOU GARY | Director | 10/28/2020 | 7,734 |
TARNOW MICHAEL M | Director | 06/09/2020 | 18,107 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 06/01/2020 | 22,331 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 06/01/2020 | 29,299 |
HOLLER FRANK A | Director | 05/29/2020 | 10,986 |
PIMSTONE SIMON N. | CEO | 06/01/2020 | 43,290 |
PIMSTONE SIMON N. | CEO | 05/29/2020 | 69,950 |
PIMSTONE SIMON N. | CEO | 05/26/2020 | 16,509 |
PIMSTONE SIMON N. | CEO | 05/26/2020 | 21,972 |
AZAB MOHAMMAD | Director | 12/16/2019 | 10,986 |
PATOU GARY | Director | 12/04/2019 | 7,323 |
TARNOW MICHAEL M | Director | 11/21/2019 | 25,533 |
PIMSTONE SIMON N. | CEO | 09/20/2019 | 98,856 |
HOLLER FRANK A | Director | 09/20/2019 | 48,884 |
HOLLER FRANK A | Director | 09/19/2019 | 70,452 |
PIMSTONE SIMON N. | CEO | 09/17/2019 | 162,651 |
PIMSTONE SIMON N. | CEO | 09/17/2019 | 203,381 |
HOLLER FRANK A | Director | 09/18/2019 | 40,535 |
HOLLER FRANK A | Director | 09/17/2019 | 47,243 |
AZAB MOHAMMAD | Director | 09/13/2019 | 214 |
HOLLER FRANK A | Director | 09/12/2019 | 90,508 |
HOLLER FRANK A | Director | 09/12/2019 | 98,052 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/12/2019 | 17,522 |
ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/12/2019 | 18,948 |
TARNOW MICHAEL M | Director | 05/21/2019 | 6,603 |
Hayden Michael R | Director | 03/19/2019 | 69,547 |
PATOU GARY | Director | 12/14/2018 | 6,315 |
COHEN CHARLES J. | VP, Biology | 12/11/2018 | 11,508 |
COHEN CHARLES J. | VP, Biology | 12/11/2018 | 12,633 |
AZAB MOHAMMAD | Director | 12/06/2018 | 9,474 |
TARNOW MICHAEL M | Director | 06/21/2018 | 42,354 |
AZAB MOHAMMAD | Director | 06/21/2018 | 38,066 |
PATOU GARY | Director | 06/14/2018 | 23,705 |
PATOU GARY | Director | 06/14/2018 | 30,451 |
ROBIN SHERRINGTON | EVP Bus. & Corp. Development | 03/15/2018 | 8,917 |
ROBIN SHERRINGTON | EVP Bus. & Corp. Development | 03/15/2018 | 11,634 |
HOLLER FRANK A | Director | 03/14/2018 | 11,634 |
PIMSTONE SIMON N. | CEO | 03/12/2018 | 38,786 |
COHEN CHARLES J. | VP, Biology | 02/12/2018 | 79,342 |
COHEN CHARLES J. | VP, Biology | 02/12/2018 | 99,235 |
AZAB MOHAMMAD | Director | 11/15/2017 | 33,280 |
AZAB MOHAMMAD | Director | 09/22/2017 | 23,600 |
AZAB MOHAMMAD | Director | 09/21/2017 | 5,900 |
AZAB MOHAMMAD | Director | 08/18/2017 | 18,302 |
AZAB MOHAMMAD | Director | 08/17/2017 | 61 |
WINQUIST RAYMOND | Head, Translational Research | 08/18/2017 | 2,995 |
EMPFIELD JAMES R. | SVP, Drug Discovery | 08/15/2017 | 24,824 |
BVF PARTNERS L P/IL | 10% Owner | 08/15/2017 | 45,489 |
BVF PARTNERS L P/IL | 10% Owner | 08/14/2017 | 111,778 |
Svoronos Dawn | Director | 08/14/2017 | 140,770 |
PATOU GARY | Director | 08/10/2017 | 20,836 |
MORTIMER IAN | CFO & COO | 08/10/2017 | 29,000 |
MORTIMER IAN | CFO & COO | 08/10/2017 | 14,225 |
SCHELLER RICHARD H | Director | 08/10/2017 | 19,950 |
PIMSTONE SIMON N. | President & CEO | 08/10/2017 | 17,400 |
Hayden Michael R | Director | 08/14/2017 | 41,247 |
GANNON STEVEN | Director | 08/11/2017 | 42,267 |
PATOU GARY | Director | 08/08/2017 | 15,002 |
BVF PARTNERS L P/IL | 10% Owner | 06/27/2017 | 259,468 |
BVF PARTNERS L P/IL | 10% Owner | 06/27/2017 | 341,844 |
BVF PARTNERS L P/IL | 10% Owner | 06/22/2017 | 33,052 |
BVF PARTNERS L P/IL | 10% Owner | 06/21/2017 | 48,592 |
TARNOW MICHAEL M | Director | 06/19/2017 | 3,608 |
BVF PARTNERS L P/IL | 10% Owner | 06/15/2017 | 45,196 |
BVF PARTNERS L P/IL | 10% Owner | 06/19/2017 | 13,841 |
BVF PARTNERS L P/IL | 10% Owner | 06/16/2017 | 42,481 |
BVF PARTNERS L P/IL | 10% Owner | 06/07/2017 | 800,237 |
BVF PARTNERS L P/IL | 10% Owner | 06/06/2017 | 565,909 |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 05/12/2017 | 5,622 |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 05/12/2017 | 6,603 |
Hayden Michael R | Director | 03/14/2017 | 40,711 |
Hayden Michael R | Director | 03/14/2017 | 182,200 |
HOLLER FRANK A | Director | 12/15/2016 | 235,500 |
TARNOW MICHAEL M | Director | 12/12/2016 | 46,234 |
PATOU GARY | Director | 12/06/2016 | 34,784 |
PATOU GARY | Director | 12/06/2016 | 39,627 |
AZAB MOHAMMAD | Director | 12/01/2016 | 34,382 |
AZAB MOHAMMAD | Director | 12/01/2016 | 39,627 |
HOLLER FRANK A | Director | 08/19/2016 | 91,338 |
HOLLER FRANK A | Director | 08/18/2016 | 73,912 |
HOLLER FRANK A | Director | 08/17/2016 | 12,624 |
HOLLER FRANK A | Director | 08/16/2016 | 56,620 |
PIMSTONE SIMON N. | President & CEO | 07/29/2016 | 35,084 |
PIMSTONE SIMON N. | President & CEO | 07/29/2016 | 40,738 |
MORTIMER IAN | CFO & COO | 06/24/2016 | 6,150 |
MORTIMER IAN | CFO & COO | 06/24/2016 | 26,790 |
Hayden Michael R | Director | 05/25/2016 | 27,159 |
TARNOW MICHAEL M | Director | 04/28/2016 | 5,169 |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 12/16/2015 | 1,818 |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 12/16/2015 | 2,145 |
AZAB MOHAMMAD | Director | 12/11/2015 | 12,888 |
HOLLER FRANK A | Director | 11/24/2015 | 9,343 |
HOLLER FRANK A | Director | 11/24/2015 | 10,738 |
PATOU GARY | Director | 11/04/2015 | 16,266 |
PATOU GARY | Director | 11/04/2015 | 18,254 |
TARNOW MICHAEL M | Director | 11/02/2015 | 26,314 |
GOLDBERG Y. PAUL | VP of Clinical Development | 09/22/2015 | 79,499 |
GOLDBERG Y. PAUL | VP of Clinical Development | 09/22/2015 | 98,513 |
GOLDBERG Y. PAUL | VP of Clinical Development | 09/24/2015 | 103,200 |
GOLDBERG Y. PAUL | VP of Clinical Development | 09/23/2015 | 36,080 |
GOLDBERG Y. PAUL | VP of Clinical Development | 09/22/2015 | 57,384 |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 08/18/2015 | 14,322 |
ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 08/18/2015 | 15,189 |
PIMSTONE SIMON N. | President & CEO | 08/18/2015 | 95,458 |
PIMSTONE SIMON N. | President & CEO | 08/18/2015 | 101,594 |
HOLLER FRANK A | Director | 08/18/2015 | 9,548 |
HOLLER FRANK A | Director | 08/18/2015 | 10,244 |
GOLDBERG Y. PAUL | VP of Clinical Development | 08/18/2015 | 14,322 |
GOLDBERG Y. PAUL | VP of Clinical Development | 08/18/2015 | 15,189 |
TARNOW MICHAEL M | Director | 06/17/2015 | 7,638 |
Hayden Michael R | Director | 02/03/2015 | 24,743 |
PATOU GARY | Director | 01/07/2015 | 21,233 |
PATOU GARY | Director | 01/07/2015 | 17,415 |
TARNOW MICHAEL M | Director | 01/08/2015 | 25,104 |
Hayden Michael R | Director | 01/08/2015 | 25,617 |
AZAB MOHAMMAD | Director | 01/08/2015 | 12,296 |
PATOU GARY | Director | 01/07/2015 | 17,415 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
DRIEHAUS CAPITAL MANAGEMENT LLC | 4,345,180 | 2.41% | -3.72% | Growth |
CAPITAL WORLD INVESTORS | 2,681,537 | 0.02% | 17.87% | Growth At A Reasonable Price |
BLACKROCK INC. | 2,067,063 | 0.00243% | 108.49% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,048,725 | 0.1% | 90.68% | Other |
BAKER BROS. ADVISORS LP | 993,679 | 0.52% | 32.2% | Other |
ORBIMED ADVISORS LLC | 550,000 | 0.51% | -42.64% | Other |
CANDRIAM S.C.A. | 530,884 | 0.17% | -6.84% | Other |
BAMCO INC /NY/ | 100,100 | 0.01% | No change | Growth At A Reasonable Price |
D. E. SHAW & CO., INC. | 84,153 | 0.00339% | 107.54% | Other |
TIG ADVISORS, LLC | 64,200 (Call) | 0.37% | New | Event Driven |
GEODE CAPITAL MANAGEMENT, LLC | 62,073 | 0.0003% | 10.95% | Other |
ALPS ADVISORS INC | 50,780 | 0.02% | 7.25% | Other |
TUDOR INVESTMENT CORP ET AL | 43,221 | 0.02% | New | Event Driven, Other |
RENAISSANCE TECHNOLOGIES LLC | 32,600 | 0.00232% | 48.86% | Other |
BALYASNY ASSET MANAGEMENT L.P. | 15,851 | 0.00137% | New | Event Driven |
UBS OCONNOR LLC | 14,676 | 0.05% | -69.85% | Value |
Period of Report: 09/30/2023
10-K/10-Q Filings: View